DAC

Agreement for accessing data of NGS based ctDNA tests

Dac ID Contact Person Email Access Information
EGAC00001000598 Xue Wu xue [dot] wu [at] geneseeq [dot] com No additional information is available

This DAC controls 5 datasets:

Dataset ID Description Technology Samples
EGAD00001003176 For each subject, genomic DNA from whole blood, circulating cell free DNA and tumor tissues (whenever possible) were performed targeting next generation sequencing on Illumina Miseq or Hiseq 4000 platforms. The sequencing results of whole blood were used to distinguish germline and somatic mutations. Specimens were collected from patients with different kinds of solid tumors, but most are lung cancer patients. Illumina HiSeq 4000,Illumina MiSeq 1845
EGAD00001004164 Whole exome and RNA-seq of matched normal gastric mucosa (n=34) and gastric cancer tissues (n=34) from gastric cancer patients (n=34) Illumina HiSeq 4000 136
EGAD00001005798 The sequencing results provided in this study is enriched through liquid phase hybridization capture. The data set shows 35 clinical cfDNA samples showing a dominant peak at 166bp and 35 clinical cfDNA samples showing a dominant peak at 134/144bp. HiSeq X Ten,Illumina HiSeq 4000,Illumina MiSeq 70
EGAD00001006213 WES data of paired primary and metastatic tumors HiSeq X Ten,Illumina HiSeq 4000 179
EGAD00001006287 NGS data of 12 patients enrolled in the Chinese Patient Assistance Program from multiple centers who received pemetrexed alone or combined with platinum as initial chemotherapy and continued pemetrexed maintenance therapy for advanced lung adenocarcinoma from November 2014 to June 2017. HiSeq X Ten,Illumina HiSeq 4000 12